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Abstract
Introduction: Use of risk scoring systems in patients with acute coronary syndrome helps 
with summarizing important prognostic data of the disease and facilitates calculating 
confidence limits and comparing survival rates between different treatments. In the present 
study, the researchers first aimed at assessing mid-term outcome of patients with non-ST 
elevation myocardial infarction (NSTEMI), and then determining main predictors of this 
outcome to improve definitive criteria for designing a risk scoring system in the population. 
Methods: In a prospective cohort study, 124 patients with NSTEMI, diagnosed according 
to ACC/AHA guidelines and hospitalized in an academic hospital in 2013, were 
consecutively assessed. Baseline characteristics were collected via interviewing, physical 
examination, and reviewing the recorded files. All the patients were followed for one and 
six months to assess mid-term outcomes regarding mortality and major adverse cardiac 
events (MACE). MACE is defined as the occurrence of at least one of the events of death, 
myocardial infarction, repeated revascularization, or re-hospitalization. 
Results: One-month death occurred in 3.2%, re-hospitalization in 4.0%, and myocardial 
infarction in none of the patients. In addition, regarding the six-month outcomes status, 
mortality rate was determined in 6.4%, re-hospitalization in 22.6%, and myocardial 
infarction in 4.8% of patients. Hence, one- and six-month MACE rates were 7.3% and 
27.4%, respectively. Furthermore, three- and six-month survival rates were estimated to 
be 96.8% and 93.6%, respectively. According to the Cox-proportion hazard modeling, 
only reduced left ventricular ejection fraction (LVEF) (HR = 0.909, P = 0.017), history 
of chronic kidney injury (HR = 8.884, P = 0.005), and Inotrope use (HR = 35.759, P = 
0.012) could predict the six-month MACE. None of the other indexes including general 
coronary risk factors, echocardiography parameters, and level of cardiac enzymes could 
predict mortality rate.
Conclusions: Patients with NSTEMI may face high six-month MACE which can be 
predicted by low LVEF, history of renal injury and use of inotrope. Therefore, to define risk 
stratification system, these indicators should be considered as well. 
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The ratio of non-ST elevation myocardial infarction 
(NSTEMI) to ST elevation myocardial infarction (STEMI) 
continues to increase, and now less than one-third of myo-
cardial infarctions (MIs) are due to STEMI [1]. Recently, 
the wide use of more sensitive tests such as analyzing serial 
high-sensitivity cardiac troponin T (hs-cTnT), which can de-
tect even small sizes of myocardial necrosis, has increase diag-
nostic accuracy and led to increasing incidence of NSTEMI 
instead of unstable angina [2-5]. Although there have been 
significant improvements in the care of patients with cardio-
vascular disease, cardiovascular death mainly by coronary 
heart disease remains the leading cause of mortality world-
wide [1]. Risk scores are simple, applicable and more accu-
rate tools at risk stratification, in which prognostic value of 
several independent risk factors on presentation are shown.
Indexes that compound several related clinical variables of 
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the same underlying pathophysiologic event are more pow-
erful than any individual variable and could improve prog-
nostic analysis in regression modeling techniques [6-8]. For 
instance, history of myocardial infarction, congestive heart 
failure, Q waves on electrocardiogram and high troponin T 
concentrations all represent different aspects of the extent of 
myocardial injury [9, 10]. In addition to the extent of myo-
cardial injury, the extent of coronary artery disease and its 
resistance to management are the main prognostic determi-
nants of acute coronary syndrome [11].
Age, heart rate, systolic blood pressure, Killip class, ST segment 
deviation, resuscitation from cardiac arrest, elevated cardiac 
enzymes and serum creatinine concentration are powerful 
prognostic factors in GRACE and PURSUIT scoring systems 
[12-14].
Seven independent predictor variables have been identified as 
TIMI risk factors including age > 65 years, three cardiovascu-
lar risk factors, known coronary artery disease (50% stenosis), 
severe angina symptoms, use of aspirin in the last seven days, 
ST segment deviation > 0.05 mV, and elevated serum cardiac 
markers of necrosis [15, 16]  
Use of risk scoring systems in patients with acute coronary 
syndrome helps to summarize important prognostic data of 
the disease and facilitates comparing survival rate between dif-
ferent treatments [17, 18].
In the present study, we aimed to first assess mid-term outcome 
of patients with NSTEMI, and then determine main predictors 
of this outcome. 
METHODS 
In a prospective cohort study, 124 patients with diagnosed 
NSTEMI according to ACC/AHA guidelines, who were hos-
pitalized at Modarres hospital between March 2012 and Sep-
tember 2013, were consecutively included. Baseline character-
istics were collected via interviewing, physical examination, 
and reviewing the recorded files including demographic char-
acteristics, medical history, medication, previous cardiac inter-
vention, laboratory parameters, and functional class status. 
Patients were also assessed using two-dimensional echocar-
diography to determine structural and functional parameters 
such as left ventricular ejection fraction, end systolic and dia-
stolic diameters, and also diastolic functional indexes. They 
also underwent coronary angiography to determine presence 
and severity of coronary arteries involvement.
To assess mid-term outcomes of NSTEMI, all the patients 
were followed for one and six months to evaluate mid-term 
outcomes regarding mortality and major adverse cardiac 
events (MACE), defined as the occurrence of at least one of 
the events of myocardial infarction, repeated revascularization, 
or re-hospitalization.
Results were presented as mean ± standard deviation (SD) for 
quantitative variables and were summarized by frequency (%) 
for categorical variables. Continuous variables were compared 
using t-test or non-parametric Mann-Whitney U test, whenev-
er the data did not appear to have normal distribution or when 
the assumption of equal variances was violated across the two 
study groups. Categorical variables were, on the other hand, 
compared using chi-squared test or Fisher’s exact test when 
more than 20% of cells with expected count of less than five 
were observed. Cox proportional hazard model was used to 
determine main correlates of MACE. Statistical analysis was 
performed by SPSS version 21.0 (SPSS Inc., Chicago, IL). P 
values of 0.05 or less were considered statistically significant.
RESULTS 
Totally, 124 patients were included in the study. The mean age 
of patients was 62.40 ± 11.07, ranging 35 to 93 years. Baseline 
demographic and clinical characteristics of patients are shown 
in Table 1.
 Table1: Baseline Demographical and Clinical Characteristics in
Patients with Non-ST Elevation Myocardial Infarction
Variables Amount
Demographics
Age (y) 62.4 ± 11.7
BMI (k/m2) 26.28 ± 2.95









Peripheral arterial disease 11.3
Prior heart failure 27.4
Prior cerebrovascular events 8.1
Prior renal failure 12.1
Chronic lung disease 15.3







Typical chest pain (%) 65.3
Chest pain + Dyspnea (%) 33.1
Atypical chest pain (%) 1.6
Initial heart rate (beats/min) 85.02 ±1.49
Initial systolic BP (mm Hg) 130.85 ± 26.22
ECG Findings (%)
Pathologic Q wave 7.0
ST depression 68.5
Transient ST elevation 4.0
Laboratory Results
Peak Troponin (μg/l) 3.08 ± 2.48
Peak CPK (IU/L) 631 ± 5.00
Peak CK.MB (IU/L) 87.06 ± 6.83
Hemoglobin (g/dL) 14.07 ± 1.68
Serum creatinine (mg/dL) 1.25 ± 0.32
TIMI Risk Score (%)
Low risk (score 0-2) 6.5
 Intermediate risk (score 3-4) 56.5
 High risk (5-7) 37.1
Values are presented as percentages or mean± SD.
BP: Blood pressure; BMI: Body mass index; CABG: Coronary ar-
 tery bypass grafting; ECG: Electrocardiogram; TIMI: Thrombolysis
in Myocardial Infarction; PCI: Percutaneous coronary intervention.
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The most common traditional cardiovascular risk factors 
were hypertension (56.5%), followed by hyperlipidemia, 
current smoking, diabetes mellitus, and obesity. Nearly one 
third of patient (27.8%) had history of coronary revascular-
ization, percutaneous coronary intervention (PCI) or coro-
nary artery bypass grafting (CABG); about half had histo-
ry of previous aspirin administration. Medical treatments 
during hospitalization, echocardiography and angiography 
findings are demonstrated in Table 2. Only a few patients 
(0.8%) received low molecular weight heparin instead of un-
fractionated heparin.
Approximately 96% of the patients underwent cardiac cathe-
terization (37.1% within 24 hours from index admission and 
58.1% after 24 hours), whereas 62.2% experienced percutane-
ous coronary intervention, 15.3% endured bypass surgery, and 
22.5% were treated conservatively.
Based on the angiography report, three coronary vessel in-
volvements were the most frequent results, followed by two 
vessel diseases (VD), one VD and left main disease (Table 2). 
Regarding the one-month outcomes, one-month death oc-
curred in 3.2%, re-hospitalization in 4.0%, CABG in 0.8%, 
and myocardial infarction in none of the patients. In addi-
tion, regarding the six-month outcomes, mortality rate was 
determined in 6.4%, re-hospitalization in 22.6%, CABG in 
3.2%, and myocardial infarction in 4.8% of patients. Hence, 
one- and six-month MACE rates were 7.3% and 27.4%, re-
spectively; survival rates at one and six months were 96.8% 
and 93.6%, respectively.
According to univariate analysis, different variants pre-
dict six-month MACE (Table 3); however, based on the 
Cox-proportion hazard modeling, only reduced left ven-
tricular ejection fraction (LVEF) (HR = 0.909, P = 0.017), 
history of chronic kidney injury (HR = 8.884, P = 0.005), 
and Inotrope usage (HR = 35.759, P = 0.012) could predict 
six-month MACE. 
In this context, none of the indexes including general coro-
nary risk factors, echocardiography parameters, and level of 
cardiac enzymes could predict mortality rate.
DISCUSSION 
According to the increasing trend of the overall incidence of 
NSTEMI compared with other components of acute coro-
nary syndrome, the assessment of this ischemic event and 
also determining its related determinants are necessary. Be-
sides, designing a risk stratification system to determine the 
level of risk in patients with NSTEMI can lead to better clini-
cal management of these patients and also to schedule appro-
priate treatment programs for these patients. 
In the present study, we first attempted to determine mid-
term outcomes of patients with NSTEMI and then aimed 
to assess main predictors of NSTEMI outcomes in the study 
population. Based on observation, the mean age of patients 
NSTEMI was 62.40 ± 11.07 years, consistent with those of 
Korea Acute Myocardial Infarction Registry (KAMIR) (63.6 
± 12.2 years) [19]; but, they were younger than patients with 
NSTEMI in Malopolska Registry of Acute Coronary Syn-
dromes performed by Dziewierz et al. (70.2 ± 11.6 years) 
[20]. The most frequent cardiovascular risk factor was hy-
pertension, consistent with most NSTEMI studies [19-21]; 
however, smoking and hyperlipidemia were more common in 
a cohort study [22].
In this study, the mid-term mortality rate in patients with 
NSTEMI was 6.4%. Furthermore, one- and six-month MACE 
rates were 7.3% and 27.4%, respectively. On the other hand, 
although patients with NSTEMI had an acceptable mortality 
rate, they experienced a high mid-term MACE rate; among 
every four patients, one faced with cardiac morbidities in a 
mid-term period.
In one report, 458 patients without persistent ST segment 
elevation acute coronary syndrome were assigned to early 
invasive strategy.  Hospital and overall mortality rates were 
3.3% and 4.8%; respectively. MACE was observed in 20.3% 
of patients within six months [23].
Moreover, for the patient who had been referred for catheter-
ization and the ones who underwent conservative strategy, 
Khalill et al. reported one-year mortality rate of 4% and 10%; 
respectively [24]. In another study performed by Park HW et 
al., the MACE rates for early term (one month) and late-term 
(one year) were 6.9% and 8.0%; respectively [25].
Table 2: In Hospital Medication, Echocardiography and Angi-






Aspirin + clopidegrol 67.7






LVEF (%) 43.61 ± 11.35
LVEDD (cm) 5.34 ± 0.64
 RVEDD (cm) 3.05 ± 0.28
Ea/Ee 12.44 ± 4.40










Values are presented as percentages or mean ± SD.
 LMD: Left main disease; LMWH: Low-molecular-weight heparin;
 LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular
 end diastolic diameter; MR: Mitral regurgitation; RVEDD: Right
 ventricular end diastolic diameter; SVD: Single vessel disease; 2VD:
 Two vessel disease; 3VD: Three vessel disease; TAPSE: Tricuspid
annular plane systolic excursion; UFH: Unfractionated heparin.
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Table 3: Comparison of Patients with NSTEMI according to 6-months MACE
Characteristics MACE (+), (n = 34) MACE (-), (n = 90) P value
Male gender 27 (79.4) 63 (70) 0.295
Age (y) 66.41 ± 10.64 60.88 ± 10.90 0.013
BMI (kg/m2) 25.56 ± 2.31 26.55 ± 3.13 0.097
Hypertension 23 (67.6) 43 (47.8) 0.122
Diabetes mellitus 12 (35.3) 30 (33.3) 0.837
Current Smoking 16 (47.1) 27 (30.0) 0.032
Hyperlipidemia 16 (47.1) 47 (52.2) 0.608
Prior CABG 9 (26.5) 17 (18.9) 0.019
Prior PCI 4 (11.8) 11 (12.2)  0.889
Prior heart failure 19 (55.9) 15 (16.0) < 0.001
Prior renal failure 9 (26.5) 6 (6.7) 0.003
Prior cerebrovascular events 3 (8.8) 7 (7.8) 0.849
Peripheral arterial disease 6 (17.6) 8 (8.9) 0.169
Opium 7 (20.6) 7 (7.8) 0.132
LVEF 34.44 ± 13.30 47.08 ± 8.61 < 0.001
LVEDD 5.77 ± 0.78 5.18 ± 0.49 < 0.001
RVEDD 3.12 ± 0.31 3.03 ± 0.26 0.066
TAPSE 1.7 ± 0.3 1.93 ± 0.2 0.005
Ea/Ee 13.7 ± 4.7 11.9 ± 4.3 0.060
MR
Mild 12 (35.3) 37 (41.1) 0.149
Moderate 14 (41.2) 10 (11.1) 0.001
Severe 1 (2.9) 2 (2.2) 0.889
TIMI Score 4.7 ± 1.2 3.9 ± 1.2 0.001
ACC/AHA high risk 21 (63.6) 26 (28.5) 0.001
ACC/AHA moderate risk 11 (33.3) 58 (63.7) 0.004
ACC/AHA low risk 1 (3.0) 7 (7.6) 0.32
Previous Aspirin usage 20 (60) 45 (49) 0.185
Drugs in hospitalization
Aspirin + Clopidegrol 27 (79.4) 57 (63.3) 0.251
Aspirin + Clopidegrol + Eptifibatide 7 (20.6) 33 (36.7) 0.095
UFH 34 (100) 89 (98.9) 0.537
Inotrope 6 (17.6) 1 (1.1) 0.002
Beta blockers 24 (70.6) 87 (96.7) 0.226
Pathologic Q wave 4 (11.8) 0 0.005
ST-T change 27 (79.4) 58 (64.4) 0.001
Angiography within 24h 7 (21.2) 39 (43.3) 0.035
Angiography results
SVD 1 (3.1) 15 (17.2) 0.005
2VD 7 (20.6) 30 (34.5) 0.021
3VD 15 (46.9) 27 (31.0) 0.001
LMD 3 (9.4) 5 (5.7) 0.445
Values are presented as n (%) or mean ± SD.
Abbreviations are as in Tables 1 and 2. MACE: Major adverse cardiac events.
From the CRUSADE registry, one-year mortality rate in old-
er patients with NSTEMI (aged ≥ 65 years) was 24.4%, and 
age was the most significant predictor of mortality [21]. Re-
cently, Kim et al. reported a six-months MACE ranging from 
12.4% to 23.1% based on TIMI risk score for low- to high-risk 
patients with NSTEMI, respectively, in KAMIR [19].
In the second step of study, we found that patients with MACE 
were older and more likely to be current smokers, have a his-
tory of CHF, CABG, CKD, pathologic Q wave, ST-segment 
changes, LV and RV dysfunction, moderate MR, catheteriza-
tion after 24 hours, and inotrope usage during hospitalization; 
however, the correlation of severe MR and MACE was not 
statistically significant, which may be due to insufficient total 
number of severe MRs. The TIMI risk score (TRS) system 
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had a good correlation with MACE for patients in the high-
risk group. By Cox-proportion hazard analysis, we could in-
troduce reduced LVEF, history of chronic kidney injury, and 
Inotrope use as major factors triggering mid-term MACE in 
patients with NSTEMI.
In KAMIR by Kim et al., Killip class above III, the presence 
of heart failure or cardiogenic shock and NT-ProBNP demon-
strated good correlations with MACE, and the TRS system 
had a good correlation with MACE for patients in the low and 
intermediate groups [19].
On the other hand, demographic parameters, echocardiog-
raphy indexes and also increased level of cardiac enzymes 
were not correlated with poor mid-term outcome in those 
patients. 
It seems that the type of predictors of NSTEMI consequenc-
es can be different in various populations depending on char-
acteristics of population, diagnostic criteria of MACE, fol-
low-up time, and number of patients included.
This study revealed that in a limited portion of the Iranian 
population, only three factors including reduced LVEF, histo-
ry of chronic kidney injury, and Inotrope usage could predict 
six-month MACE, suggesting that the abovementioned pa-
rameters are probably more significant than other prognostic 
factors reported.
Limitations of this study can be discussed from various 
points. First, a small number of participants was used; thus, 
the findings should be treated with care. Second, other vari-
ables could provide novel prognostic results. Third, further 
studies need to be accomplished to achieve verification of 
new scoring systems.
In conclusion, patients with NSTEMI may face high six-
month MACE, which can be predicted by low LVEF, history 
of renal injury, and use of inotrope. 
Therefore, defining a risk stratification system should be 
considered in these patients.
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